Acetylsalicylic Acid Resistance After Simultaneous Pancreas-Kidney Transplantation
Abstract Background The most common conditions leading to death after simultaneous pancreas-kidney transplantations (SPKs) are cardiovascular diseases. The aim of this study was to test the platelet aggregation inhibitor acetylsalicylic acid (ASA) resistance in patients after SPKs, including investi...
Gespeichert in:
| Veröffentlicht in: | Transplantation proceedings 2016-09, Vol.48 (7), p.2555-2557 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2557 |
|---|---|
| container_issue | 7 |
| container_start_page | 2555 |
| container_title | Transplantation proceedings |
| container_volume | 48 |
| creator | Praksch, D Sandor, B Nagy, K.K Viola, M Toth, A Toth, K Szakaly, P Varga, A |
| description | Abstract Background The most common conditions leading to death after simultaneous pancreas-kidney transplantations (SPKs) are cardiovascular diseases. The aim of this study was to test the platelet aggregation inhibitor acetylsalicylic acid (ASA) resistance in patients after SPKs, including investigations into the triggering factors. Methods Thirty-two patients (22 men, 10 women; overall age, 47.4 ± 8.6 years) were involved in our study and took 100 mg ASA per day. We used optical platelet aggregometry to detect resistance. Results Resistance occurred in 40.6% of the study group. However, with the use of logistic regression analysis, the examined 24 factors did not show any significant correspondence with resistance. Conclusions The incidence of ASA resistance seems to be higher compared with other groups, but the triggering effect is still unproved. Clarifying this question should be important regarding the mortality- and morbidity-reducing capacity of antiplatelet drugs in the management of cardiovascular conditions. |
| doi_str_mv | 10.1016/j.transproceed.2016.07.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1835417656</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0041134516303931</els_id><sourcerecordid>1835417656</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-baaebaef928336016088dc50601df6d12279c3eaeb67c465c74a9ae4d744491e3</originalsourceid><addsrcrecordid>eNqNkUtv1DAQxy0EotuWr1BFnLgk-BU74YC0KrRFVAL1cba89kTy1psU26mUb88s20qIEwfL9sx_Xr8h5D2jDaNMfdw2JdkxP6bJAfiGo62huqG0e0VWrNOi5oqL12RFqWQ1E7I9Isc5byn-uRRvyRHXWnIh9YrcrB2UJWYbg1vwVGsXfHUDOeRiRwfVeiiQqtuwmyMaYJpz9RMdCWyuvwc_wlLd_ekm2rHYEqbxlLwZbMzw7vk-IfcXX-_Or-rrH5ffztfXtRO6K_XGWthYGHreCaFwBtp13rUUn35QnnGueycARUo7qVqnpe0tSK-llD0DcUI-HPIiiF8z5GJ2ITuI8dCmYZ1oJdOqVSj9dJC6NOWcYDCPKexsWgyjZs_UbM3fTM2eqaHaIFMMPnuuM2926HsJfYGIgi8HAeC0TwGSyS4AwvMhgSvGT-H_6nz-J42LYQzOxgdYIG-nOY3I0zCTuaHmdr_d_XKZElT0gonfonulIA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835417656</pqid></control><display><type>article</type><title>Acetylsalicylic Acid Resistance After Simultaneous Pancreas-Kidney Transplantation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Praksch, D ; Sandor, B ; Nagy, K.K ; Viola, M ; Toth, A ; Toth, K ; Szakaly, P ; Varga, A</creator><creatorcontrib>Praksch, D ; Sandor, B ; Nagy, K.K ; Viola, M ; Toth, A ; Toth, K ; Szakaly, P ; Varga, A</creatorcontrib><description>Abstract Background The most common conditions leading to death after simultaneous pancreas-kidney transplantations (SPKs) are cardiovascular diseases. The aim of this study was to test the platelet aggregation inhibitor acetylsalicylic acid (ASA) resistance in patients after SPKs, including investigations into the triggering factors. Methods Thirty-two patients (22 men, 10 women; overall age, 47.4 ± 8.6 years) were involved in our study and took 100 mg ASA per day. We used optical platelet aggregometry to detect resistance. Results Resistance occurred in 40.6% of the study group. However, with the use of logistic regression analysis, the examined 24 factors did not show any significant correspondence with resistance. Conclusions The incidence of ASA resistance seems to be higher compared with other groups, but the triggering effect is still unproved. Clarifying this question should be important regarding the mortality- and morbidity-reducing capacity of antiplatelet drugs in the management of cardiovascular conditions.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2016.07.008</identifier><identifier>PMID: 27742347</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aspirin - therapeutic use ; Cardiovascular Diseases - prevention & control ; Drug Resistance ; Female ; Humans ; Kidney Transplantation - adverse effects ; Male ; Middle Aged ; Pancreas Transplantation - adverse effects ; Platelet Aggregation - drug effects ; Platelet Aggregation Inhibitors - therapeutic use ; Surgery</subject><ispartof>Transplantation proceedings, 2016-09, Vol.48 (7), p.2555-2557</ispartof><rights>Elsevier Inc.</rights><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c378t-baaebaef928336016088dc50601df6d12279c3eaeb67c465c74a9ae4d744491e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0041134516303931$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27742347$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Praksch, D</creatorcontrib><creatorcontrib>Sandor, B</creatorcontrib><creatorcontrib>Nagy, K.K</creatorcontrib><creatorcontrib>Viola, M</creatorcontrib><creatorcontrib>Toth, A</creatorcontrib><creatorcontrib>Toth, K</creatorcontrib><creatorcontrib>Szakaly, P</creatorcontrib><creatorcontrib>Varga, A</creatorcontrib><title>Acetylsalicylic Acid Resistance After Simultaneous Pancreas-Kidney Transplantation</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Abstract Background The most common conditions leading to death after simultaneous pancreas-kidney transplantations (SPKs) are cardiovascular diseases. The aim of this study was to test the platelet aggregation inhibitor acetylsalicylic acid (ASA) resistance in patients after SPKs, including investigations into the triggering factors. Methods Thirty-two patients (22 men, 10 women; overall age, 47.4 ± 8.6 years) were involved in our study and took 100 mg ASA per day. We used optical platelet aggregometry to detect resistance. Results Resistance occurred in 40.6% of the study group. However, with the use of logistic regression analysis, the examined 24 factors did not show any significant correspondence with resistance. Conclusions The incidence of ASA resistance seems to be higher compared with other groups, but the triggering effect is still unproved. Clarifying this question should be important regarding the mortality- and morbidity-reducing capacity of antiplatelet drugs in the management of cardiovascular conditions.</description><subject>Adult</subject><subject>Aged</subject><subject>Aspirin - therapeutic use</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Drug Resistance</subject><subject>Female</subject><subject>Humans</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pancreas Transplantation - adverse effects</subject><subject>Platelet Aggregation - drug effects</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Surgery</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtv1DAQxy0EotuWr1BFnLgk-BU74YC0KrRFVAL1cba89kTy1psU26mUb88s20qIEwfL9sx_Xr8h5D2jDaNMfdw2JdkxP6bJAfiGo62huqG0e0VWrNOi5oqL12RFqWQ1E7I9Isc5byn-uRRvyRHXWnIh9YrcrB2UJWYbg1vwVGsXfHUDOeRiRwfVeiiQqtuwmyMaYJpz9RMdCWyuvwc_wlLd_ekm2rHYEqbxlLwZbMzw7vk-IfcXX-_Or-rrH5ffztfXtRO6K_XGWthYGHreCaFwBtp13rUUn35QnnGueycARUo7qVqnpe0tSK-llD0DcUI-HPIiiF8z5GJ2ITuI8dCmYZ1oJdOqVSj9dJC6NOWcYDCPKexsWgyjZs_UbM3fTM2eqaHaIFMMPnuuM2926HsJfYGIgi8HAeC0TwGSyS4AwvMhgSvGT-H_6nz-J42LYQzOxgdYIG-nOY3I0zCTuaHmdr_d_XKZElT0gonfonulIA</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Praksch, D</creator><creator>Sandor, B</creator><creator>Nagy, K.K</creator><creator>Viola, M</creator><creator>Toth, A</creator><creator>Toth, K</creator><creator>Szakaly, P</creator><creator>Varga, A</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160901</creationdate><title>Acetylsalicylic Acid Resistance After Simultaneous Pancreas-Kidney Transplantation</title><author>Praksch, D ; Sandor, B ; Nagy, K.K ; Viola, M ; Toth, A ; Toth, K ; Szakaly, P ; Varga, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-baaebaef928336016088dc50601df6d12279c3eaeb67c465c74a9ae4d744491e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aspirin - therapeutic use</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Drug Resistance</topic><topic>Female</topic><topic>Humans</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pancreas Transplantation - adverse effects</topic><topic>Platelet Aggregation - drug effects</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Praksch, D</creatorcontrib><creatorcontrib>Sandor, B</creatorcontrib><creatorcontrib>Nagy, K.K</creatorcontrib><creatorcontrib>Viola, M</creatorcontrib><creatorcontrib>Toth, A</creatorcontrib><creatorcontrib>Toth, K</creatorcontrib><creatorcontrib>Szakaly, P</creatorcontrib><creatorcontrib>Varga, A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Praksch, D</au><au>Sandor, B</au><au>Nagy, K.K</au><au>Viola, M</au><au>Toth, A</au><au>Toth, K</au><au>Szakaly, P</au><au>Varga, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acetylsalicylic Acid Resistance After Simultaneous Pancreas-Kidney Transplantation</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>48</volume><issue>7</issue><spage>2555</spage><epage>2557</epage><pages>2555-2557</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><abstract>Abstract Background The most common conditions leading to death after simultaneous pancreas-kidney transplantations (SPKs) are cardiovascular diseases. The aim of this study was to test the platelet aggregation inhibitor acetylsalicylic acid (ASA) resistance in patients after SPKs, including investigations into the triggering factors. Methods Thirty-two patients (22 men, 10 women; overall age, 47.4 ± 8.6 years) were involved in our study and took 100 mg ASA per day. We used optical platelet aggregometry to detect resistance. Results Resistance occurred in 40.6% of the study group. However, with the use of logistic regression analysis, the examined 24 factors did not show any significant correspondence with resistance. Conclusions The incidence of ASA resistance seems to be higher compared with other groups, but the triggering effect is still unproved. Clarifying this question should be important regarding the mortality- and morbidity-reducing capacity of antiplatelet drugs in the management of cardiovascular conditions.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27742347</pmid><doi>10.1016/j.transproceed.2016.07.008</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0041-1345 |
| ispartof | Transplantation proceedings, 2016-09, Vol.48 (7), p.2555-2557 |
| issn | 0041-1345 1873-2623 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1835417656 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Aspirin - therapeutic use Cardiovascular Diseases - prevention & control Drug Resistance Female Humans Kidney Transplantation - adverse effects Male Middle Aged Pancreas Transplantation - adverse effects Platelet Aggregation - drug effects Platelet Aggregation Inhibitors - therapeutic use Surgery |
| title | Acetylsalicylic Acid Resistance After Simultaneous Pancreas-Kidney Transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T05%3A08%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acetylsalicylic%20Acid%20Resistance%20After%20Simultaneous%20Pancreas-Kidney%20Transplantation&rft.jtitle=Transplantation%20proceedings&rft.au=Praksch,%20D&rft.date=2016-09-01&rft.volume=48&rft.issue=7&rft.spage=2555&rft.epage=2557&rft.pages=2555-2557&rft.issn=0041-1345&rft.eissn=1873-2623&rft_id=info:doi/10.1016/j.transproceed.2016.07.008&rft_dat=%3Cproquest_cross%3E1835417656%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835417656&rft_id=info:pmid/27742347&rft_els_id=1_s2_0_S0041134516303931&rfr_iscdi=true |